Oncorus is a pre-clinical stage biotechnology company structured around developing innovative and impactful, next-generation oncolytic HSV products with unprecedented potential to recruit every component that collectively makes up the immune system to the task of treating solid tumors. Anchored in technology from the University of Pittsburgh, two treatments are currently (2019-20) under developed are designed to "alert" the immune system to begin fighting cancer tumors, as well as teaching the system what to look for and to fight next time. The firm's lead drug candidate uses an augmented version of the herpes virus to fight liver cancer, melanoma and head and neck cancers.
